









Markets
/
Stocks
/
nasdaq-wgs
/

GeneDx Holdings Corp

WGS

136.910USD

+5.410+4.11%

Close 10/31, 16:00（ET）Quotes delayed by 15 min

3.96BMarket Cap

1898.84P/E TTM



GeneDx Holdings Corp

136.910

+5.410+4.11%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of GeneDx Holdings Corp

Currency: USD Updated: 2025-10-31

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

GeneDx Holdings Corp's Score

Industry at a Glance

Industry Ranking

17 / 78

Overall Ranking

105 / 4618

Industry

Healthcare Providers & Services

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 9 analysts

Buy

Current Rating

151.222

Target Price

+15.00%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

GeneDx Holdings Corp Highlights

StrengthsRisks

GeneDx Holdings Corp. is a genomics company. The Company is focused on delivering personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The Company's segments are GeneDx inclusive of Legacy GeneDx and Legacy Sema4. The GeneDx segment primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. GeneDx utilizes an integrated portfolio of laboratory processes, software tools, and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. GeneDx provides a variety of genetic diagnostic tests, screening solutions, and information. The Legacy Sema4 diagnostics segment provides reproductive and women's health and somatic oncology diagnostic testing and screening products.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 30.15% year-on-year.

Overvalued

The company’s latest PE is 1261.61, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 31.75M shares, decreasing 0.93% quarter-over-quarter.

Held by Catherine Wood

Star Investor Catherine Wood holds 625.42K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.10.

Financial Health

Currency: USD Updated: 2025-10-31

The company's current financial score is 8.36, which is higher than the Healthcare Providers & Services industry's average of 7.24. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 116.74M, representing a year-over-year increase of 51.86%, while its net profit experienced a year-over-year increase of 8.14%.

Score

Industry at a Glance

Previous score

8.36

Change



Financials

9.24

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.28

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

8.17

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

9.62

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.48

Key Metrics

Free cash flow

No Data

GeneDx Holdings Corp's Company Valuation

Currency: USD Updated: 2025-10-31

The company’s current valuation score is 4.11, which is lower than the Healthcare Providers & Services industry's average of 7.09. Its current P/E ratio is 1261.61, which is 32.13% below the recent high of 1666.91 and 106.62% above the recent low of -83.57.

Score

Industry at a Glance

Previous score

4.11

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 17/78

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-31

The company’s current earnings forecast score is 8.50, which is higher than the Healthcare Providers & Services industry's average of 7.60. The average price target for GeneDx Holdings Corp is 160.00, with a high of 170.00 and a low of 95.00.

Score

Industry at a Glance

Previous score

8.50

Change

Support & Resistance

No Data

Analyst Rating

Based on 9 analysts

Buy

Current Rating

151.222

Target Price

+15.00%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

GeneDx Holdings Corp

WGS

CVS Health Corp

CVS

HCA Healthcare Inc

HCA

Teladoc Health Inc

TDOC

Tenet Healthcare Corp

THC

Universal Health Services Inc

UHS

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-31

The company’s current price momentum score is 9.27, which is higher than the Healthcare Providers & Services industry's average of 6.75. Sideways: Currently, the stock price is trading between the resistance level at 150.47 and the support level at 118.87, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.93

Change

0.34

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(2)

Buy(4)

Indicators

Value

Direction

MACD(12,26,9)

2.808

Buy

RSI(14)

62.793

Neutral

STOCH(KDJ)(9,3,3)

64.441

Neutral

ATR(14)

9.535

High Vlolatility

CCI(14)

103.823

Buy

Williams %R

28.766

Buy

TRIX(12,20)

0.355

Sell

StochRSI(14)

59.036

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

133.660

Buy

MA10

129.205

Buy

MA20

125.174

Buy

MA50

124.250

Buy

MA100

108.215

Buy

MA200

95.684

Buy

Institutional Confidence

Currency: USD Updated: 2025-10-31

The company’s current institutional recognition score is 10.00, which is higher than the Healthcare Providers & Services industry's average of 6.96. The latest institutional shareholding proportion is 110.52%, representing a quarter-over-quarter decrease of 7.31%. The largest institutional shareholder is The Vanguard, holding a total of 1.18M shares, representing 4.07% of shares outstanding, with 11.37% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Corvex Management LP

3.06M

Casdin Capital, LLC

3.05M

-13.16%

William Blair Investment Management, LLC

1.63M

+37.21%

Icahn School of Medicine at Mount Sinai

1.37M

-49.50%

OPKO Health Inc

1.37M

-36.88%

BlackRock Institutional Trust Company, N.A.

1.28M

+23.25%

Pentwater Capital Management LP

1.22M

+3712.50%

The Vanguard Group, Inc.

Star Investors

1.18M

+14.50%

T. Rowe Price Investment Management, Inc.

1.04M

+105.89%

UBS Financial Services, Inc.

1.00M

+1895.62%

Risk Assessment

Currency: USD Updated: 2025-10-31

The company’s current risk assessment score is 5.01, which is lower than the Healthcare Providers & Services industry's average of 5.45. The company's beta value is 2.07. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.